Is the price fair?
What ACAD's price assumes
ACADIA Pharmaceuticals Inc. trades at 13.4× earnings against 32.4× for the median Biotechnology name, cheaper than its own group.
13.4
Trailing P/E · Biotechnology median 32.4 · cheaper than the typical name in its group
- Price / sales
- 3.51
Price / sales · as of 2026-Q1
- Free cash flow yield
- 3.1%
Free cash flow yield · Biotechnology median 2.5%
- Growth the price implies
- +12%
Growth the price implies · The price pays for +12% free cash flow growth a year for a decade; revenue has grown +28% a year over the last three.
Details›
- Price / book2026-Q1
- 3.08
- Healthcare median P/E362 names
- 31.5
- Biotechnology median P/E158 names
- 32.4
- Free cash flow, trailing twelve months
- $114M
- Market capitalisation
- $3.70B
- 3-year revenue growth
- +28%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.